Journal
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
Volume 10, Issue 9, Pages 926-929Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jpids/piab029
Keywords
bradycardia; COVID-19; pediatrics; remdesivir; SARS-CoV-2
Categories
Funding
- National Institute of Allergy and Infectious Diseases [K08AI150996-01]
Ask authors/readers for more resources
This article describes a case of sinus bradycardia associated with Remdesivir therapy in a pediatric patient with severe COVID-19.
Remdesivir is an RNA polymerase inhibitor that is commonly used in the treatment of patients with severe acute coronavirus disease 2019 (COVID-19). As the severe acute respiratory syndrome coronavirus 2 spreads, the use of remdesivir is likely to increase. Most of the patients treated with remdesivir will not experience any adverse events although some side effects have been reported. Here, we describe a case of sinus bradycardia associated with remdesivir therapy in a pediatric patient with severe acute COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available